Search Results 451-460 of 16625 for alopecia

1. Prader-Willi syndrome - Diagnosis and treatment - Mayo Clinic

   This rare genetic condition leads to physical, mental and behavioral problems, including being hungry all the time.

2. A Blanket Protocol to Study Oral Regorafenib in Patients with Selected Sarcoma Subtypes - Mayo Clinic

   All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent ...

3. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

   In addition, any drug-related toxicity except alopecia should have recovered to Grade 1 or less. Prior therapy with any ERK inhibitor (e.g., LY3214996 ...

4. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

   03) > Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia. Any grade of neuropathy from any cause. Any prior oxaliplatin ...

5. A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma - Mayo Clinic

   ... alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction); Has had within the past 6 months the occurrence or persistence of one or more of the ...

6. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1; Patients who are ...

7. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction - Mayo Clinic

   ... alopecia; Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral ...

8. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

   current) related to prior anticancer therapy (excluding alopecia, lymphopenia, peripheral neuropathy, and ototoxicity, which are excluded only if ≥ Grade 3) ...

9. Lurbinectedin + Doxorubicin In Leiomyosarcoma - Mayo Clinic

   Participants who have not recovered to ≤ Grade 1 or baseline from adverse events attributed to any prior anti-cancer therapy, with the exceptions of alopecia ...

10. Tucatinib and Trastuzumab for Patients with HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

    Alopecia and neuropathy, which must have resolved to ≤ Grade 2;; Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of ...